Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II capecitabine + erlotinib first-line study in metastatic pancreatic cancer
2007-003206-96Phase 2Active
- Sponsor
- Grupo Oncológico Gallego
- Start
- Nov 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and erlotinib in pancreatic cancer (PC), sponsored by Grupo Oncológico Gallego. Primary endpoint: Objective response rate. Started Nov 2007; status: active.
02
Drugs
capecitabineerlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2007-003206-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003206-96.